You are here

Diabetes Drug Albiglutide Submitted for FDA Review

Treatment replenishes GI peptide involved in insulin release (Jan. 14)

Albiglutide (GlaxoSmithKline) — an investigational once-weekly treatment for adults with type 2 diabetes — has been submitted to the FDA for review.

Albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. GLP-1 is a peptide that is normally secreted from the gastrointestinal tract during a meal, which in turn helps release insulin to control blood sugar elevations after eating. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced or absent.

Albiglutide consists of two copies of modified human GLP-1 fused in series to human albumin and is designed to have a longer duration of action than endogenous GLP-1.

Last year, positive results were reported from the Harmony 8 phase III trial, in which albiglutide was compared with a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin (Januvia, Merck Sharpe & Dohme), in 507 patients with type 2 diabetes and renal impairment.

At the 26-week primary endpoint, albiglutide showed clinically and statistically significant reductions in hemoglobin A1c from baseline (8.08% for albiglutide vs. 8.22% for sitagliptin) and superiority versus sitagliptin (reduction of –0.83% vs. –0.52%, respectively; P P = 0.0003 for superiority). At the primary endpoint, weight loss was significantly greater in the albiglutide group than in the sitagliptin group (–0.79 kg vs. –0.19 kg, respectively; P = 0.0281).

Sources: GSK; January 14, 2013; and GSK; July 11, 2012.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs